Back to Search
Start Over
Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplementary Figure from A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....15fba7a4c3002c9cc8f82b28dcf07d21
- Full Text :
- https://doi.org/10.1158/1078-0432.22487043